Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region - Global Forecast to 2028
The global immunoassay market is valued at an estimated USD 35.0 billion in 2023 and is projected to reach USD 46.7 billion by 2028, at a CAGR of 5.9% during the forecast period. Market growth is driven by factors such as the rising prevalence of chronic and infectious diseases, innovations in the systems and technologies, supportive government policies and initiatives, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
“The reagents & kits to register the largest share of the immunoassay market, by product.”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
“Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period.”
The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.
“Infectious diseases segment accounted for the largest share in the immunoassay market, by application.”
The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.
“Asia Pacific: The fastest-growing region in the immunoassay market.”
The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.
The break-up of the profile of primary participants in the immunoassay market:
Research Coverage:
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The reagents & kits to register the largest share of the immunoassay market, by product.”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
“Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period.”
The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.
“Infectious diseases segment accounted for the largest share in the immunoassay market, by application.”
The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.
“Asia Pacific: The fastest-growing region in the immunoassay market.”
The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.
The break-up of the profile of primary participants in the immunoassay market:
- By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 – 31%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Latin America – 6% and Middle East & Africa – 11%,
Research Coverage:
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, in systems and technologies, growth in biotechnology and biopharmaceutical industries, increasing adoption of immunoassay-based POC testing and rapid testing, supportive government policies, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavourable reimbursement scenario, and financial hurdles faced by physicians) influencing the growth of the immunoassay market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the immunoassay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US)among others in the immunoassay market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 IMPACT OF RECESSION: IMMUNOASSAY MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
2.8 IMPACT OF RECESSION ON IMMUNOASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET
4 PREMIUM INSIGHTS
4.1 IMMUNOASSAY MARKET OVERVIEW
FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022
4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET, 2023–2028
FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 REGIONAL MIX: IMMUNOASSAY MARKET, 2021–2028
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
4.5 DEVELOPED VS. EMERGING ECONOMIES: IMMUNOASSAY MARKET, 2023–2028
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases
FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION)
5.2.1.1.1 Growing use of immunoassays in oncology
TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020
TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020
5.2.1.1.2 Increasing use of immunoassays in diagnostic applications
TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING
5.2.1.1.3 Growing geriatric population
FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)
5.2.1.2 Increasing need for blood donations
5.2.1.3 Growth in biotechnology & biopharmaceutical industries
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
5.2.1.5 Supportive government regulatory policies and initiatives
5.2.1.6 Increased drug abuse and use of cannabis
5.2.2 RESTRAINTS
5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables
5.2.2.2 Technical problems in immunoassay kits
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics
TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022
5.2.3.3 Development of condition-specific biomarkers and tests
TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023
5.2.3.4 Integration of microfluidics in immunoassays
TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS
5.2.3.5 Improved immunoassay diagnostic technologies
5.2.4 CHALLENGES
5.2.4.1 Design challenges, complexities, and low quality of antibodies
5.2.4.2 Dearth of skilled professionals
5.2.4.3 Unfavorable reimbursement scenario
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.1.1 US
TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
5.3.1.2 Canada
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.3.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
5.3.2.1 Russia
TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.3.3 ASIA PACIFIC
5.3.3.1 Japan
FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.3.2 China
TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.3.3 India
FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.3.3.4 Indonesia
TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.3.3.5 South Korea
TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.4 LATIN AMERICA
5.3.4.1 Mexico
FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.4.2 Brazil
FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.3.5 MIDDLE EAST
5.3.5.1 Saudi Arabia
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.6 AFRICA
5.4 TECHNOLOGY ANALYSIS
TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS
TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
5.6 PATENT ANALYSIS
5.7 VALUE CHAIN ANALYSIS
FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9 ECOSYSTEM/MARKET MAP
FIGURE 31 ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET
5.9.1 ROLE IN ECOSYSTEM
5.9.2 KEY PLAYERS IN IMMUNOASSAY MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 22 PORTER’S FIVE FORCES
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT FROM NEW ENTRANTS
5.11 KEY CONFERENCES & EVENTS IN 2023–2024
TABLE 23 KEY CONFERENCES & EVENTS IN 2023–2024
5.12 PRICING ANALYSIS
TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 26 KEY BUYING CRITERIA, BY TOP END USER
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 IMMUNOASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 27 IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 28 KEY REAGENTS & KITS AVAILABLE
TABLE 29 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
6.2.1 ELISA REAGENTS & KITS
6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.2 RAPID TEST REAGENTS & KITS
6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment
TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.3 ELISPOT REAGENTS & KITS
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment
TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.4 CLIA REAGENTS & KITS
6.2.4.1 Better diagnosis and higher specificity to drive segment
TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.5 IFA REAGENTS & KITS
6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment
TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.6 WESTERN BLOT REAGENTS & KITS
6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.7 OTHER REAGENTS & KITS
TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 ANALYZERS
TABLE 38 KEY ANALYZERS AVAILABLE
TABLE 39 IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE
TABLE 40 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
6.3.1.1 Open-ended systems
6.3.1.1.1 Better flexibility and wider availability to drive segment
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.2 Closed-ended systems
6.3.1.2.1 Higher precision and better automation to drive segment
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.2 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE
TABLE 43 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
6.3.2.1 Rental purchase
6.3.2.1.1 Increased convenience and lack of liability to drive segment
TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.2.2 Outright purchase
6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market
TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 IMMUNOASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 ELISA
7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE
TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION)
7.3 CLIA
7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET
TABLE 49 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021–2028 (USD MILLION)
7.4 IFA
7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
TABLE 50 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION)
7.5 RAPID TESTS
7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET
TABLE 51 KEY RAPID TESTS AVAILABLE
TABLE 52 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION)
7.6 WESTERN BLOTTING
7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET
TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE
TABLE 54 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION)
7.7 ELISPOT
7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET
TABLE 55 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION)
7.8 OTHER TECHNOLOGIES
TABLE 56 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 IMMUNOASSAY MARKET, BY SPECIMEN
8.1 INTRODUCTION
TABLE 57 IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
8.2 BLOOD
8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET
TABLE 58 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
8.3 SALIVA
8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
TABLE 59 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
8.4 URINE
8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET
TABLE 60 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SPECIMENS
TABLE 61 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2028 (USD MILLION)
9 IMMUNOASSAY MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 62 IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 63 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
TABLE 64 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 CARDIOLOGY
9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS
TABLE 66 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.5 AUTOIMMUNE DISORDERS
9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
TABLE 67 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET
TABLE 68 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
9.7 ONCOLOGY
9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET
TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
TABLE 70 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.8 BONE & MINERAL DISORDERS
9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET
TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
TABLE 72 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.9 DRUG MONITORING AND TESTING
9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
TABLE 73 KEY PRODUCTS FOR DRUG MONITORING
TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING
TABLE 75 IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING, BY REGION, 2021–2028 (USD MILLION)
9.10 BLOOD SCREENING
9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET
TABLE 76 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING
TABLE 78 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.12 OTHER APPLICATIONS
TABLE 79 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 IMMUNOASSAY MARKET, BY END USER
10.1 INTRODUCTION
TABLE 80 IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET
TABLE 81 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
TABLE 82 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET
TABLE 83 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.5 HOME CARE SETTINGS
10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET
TABLE 84 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
10.6 BLOOD BANKS
10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET
TABLE 85 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
10.7 RESEARCH & ACADEMIC LABORATORIES
10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET
TABLE 86 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
11 IMMUNOASSAY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 87 IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 88 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market
TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 101 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 103 US: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 US: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market
TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 106 CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 109 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 110 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 111 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 112 CANADA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 118 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 121 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Germany to dominate European immunoassay market during forecast period
TABLE 122 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 128 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 ITALY
11.3.3.1 Growing geriatric population and increasing support for research to drive market
TABLE 130 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 134 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 136 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market
TABLE 138 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 139 FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 142 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 143 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 144 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market
TABLE 146 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 147 SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 150 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 151 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 152 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 UK
11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
TABLE 154 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 155 UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 158 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 159 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 160 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 RUSSIA
11.3.7.1 Lack of reimbursement and delays in approval to limit market
TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 163 RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 166 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 167 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 168 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.8 REST OF EUROPE
TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 171 REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 173 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 174 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 175 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 176 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
TABLE 178 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 183 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 185 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 JAPAN
11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market
TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 188 JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 189 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 191 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 192 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 193 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Increasing government investment and rising geriatric population to drive market
TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 196 CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 199 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 200 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 201 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 204 INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 205 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 207 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 208 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 209 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market
TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 212 AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 214 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 215 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 216 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 217 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising healthcare spending and investments in research to drive market
TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 220 SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 221 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 223 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 224 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 225 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.7 INDONESIA
11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market
TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 228 INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 230 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 231 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 232 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 233 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.8 REST OF ASIA PACIFIC
TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 239 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 240 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 241 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 LATIN AMERICA
TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 244 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 246 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 248 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 249 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022
TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 253 BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 255 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 256 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 257 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 258 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Increasing geriatric population and rising medical tourism to drive market
TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 261 MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 262 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 263 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 264 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 265 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 266 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET
12.3 REVENUE ANALYSIS
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY MARKET
FIGURE 37 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 COMPANY EVALUATION MATRIX, 2022
12.5.5 COMPANY FOOTPRINT
TABLE 286 OVERALL FOOTPRINT
TABLE 287 PRODUCT FOOTPRINT
TABLE 288 REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET
12.7 COMPETITIVE SCENARIOS AND TRENDS
12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023
12.7.2 KEY DEALS
TABLE 291 KEY DEALS, JANUARY 2020–SEPTEMBER 2023
12.7.3 OTHER KEY DEVELOPMENTS
TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ABBOTT LABORATORIES
TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
13.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.3 SIEMENS HEALTHINEERS AG
TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
13.1.4 DANAHER CORPORATION
TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.5 THERMO FISHER SCIENTIFIC INC.
TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
13.1.6 REVVITY
TABLE 298 REVVITY: COMPANY OVERVIEW
FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022)
13.1.7 BECTON, DICKINSON AND COMPANY
TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.8 DIASORIN S.P.A.
TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.9 BIO-RAD LABORATORIES, INC.
TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
13.1.10 QUIDELORTHO CORPORATION
TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
13.1.11 BIOMЙRIEUX
TABLE 303 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 50 BIOMЙRIEUX: COMPANY SNAPSHOT (2022)
13.1.12 QIAGEN N.V.
TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
13.1.13 SYSMEX CORPORATION
TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
13.1.14 AGILENT TECHNOLOGIES, INC.
TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 MERCK KGAA
13.2.2 MERIDIAN BIOSCIENCE
13.2.3 BIO-TECHNE
13.2.4 CELLABS
13.2.5 ABNOVA CORPORATION
13.2.6 J. MITRA & CO. PVT. LTD.
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE)
13.2.8 CELL SCIENCES
13.2.9 ENZO BIOCHEM
13.2.10 CREATIVE DIAGNOSTICS
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
13.2.12 ELABSCIENCE
13.2.13 WAK-CHEMIE MEDICAL
13.2.14 SERACARE LIFESCIENCES INC.
13.2.15 EPITOPE DIAGNOSTICS
13.2.16 KAMIYA BIOMEDICAL COMPANY
13.2.17 GYROS PROTEIN TECHNOLOGIES
13.2.18 TRIVITRON HEALTHCARE
13.2.19 INBIOS INTERNATIONAL, INC.
13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 IMPACT OF RECESSION: IMMUNOASSAY MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
2.8 IMPACT OF RECESSION ON IMMUNOASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET
4 PREMIUM INSIGHTS
4.1 IMMUNOASSAY MARKET OVERVIEW
FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022
4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET, 2023–2028
FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 REGIONAL MIX: IMMUNOASSAY MARKET, 2021–2028
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
4.5 DEVELOPED VS. EMERGING ECONOMIES: IMMUNOASSAY MARKET, 2023–2028
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases
FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION)
5.2.1.1.1 Growing use of immunoassays in oncology
TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020
TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020
5.2.1.1.2 Increasing use of immunoassays in diagnostic applications
TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING
5.2.1.1.3 Growing geriatric population
FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)
5.2.1.2 Increasing need for blood donations
5.2.1.3 Growth in biotechnology & biopharmaceutical industries
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
5.2.1.5 Supportive government regulatory policies and initiatives
5.2.1.6 Increased drug abuse and use of cannabis
5.2.2 RESTRAINTS
5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables
5.2.2.2 Technical problems in immunoassay kits
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics
TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022
5.2.3.3 Development of condition-specific biomarkers and tests
TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023
5.2.3.4 Integration of microfluidics in immunoassays
TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS
5.2.3.5 Improved immunoassay diagnostic technologies
5.2.4 CHALLENGES
5.2.4.1 Design challenges, complexities, and low quality of antibodies
5.2.4.2 Dearth of skilled professionals
5.2.4.3 Unfavorable reimbursement scenario
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.1.1 US
TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
5.3.1.2 Canada
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.3.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
5.3.2.1 Russia
TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.3.3 ASIA PACIFIC
5.3.3.1 Japan
FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.3.2 China
TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.3.3 India
FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.3.3.4 Indonesia
TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.3.3.5 South Korea
TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.4 LATIN AMERICA
5.3.4.1 Mexico
FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.4.2 Brazil
FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.3.5 MIDDLE EAST
5.3.5.1 Saudi Arabia
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.6 AFRICA
5.4 TECHNOLOGY ANALYSIS
TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS
TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
5.6 PATENT ANALYSIS
5.7 VALUE CHAIN ANALYSIS
FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9 ECOSYSTEM/MARKET MAP
FIGURE 31 ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET
5.9.1 ROLE IN ECOSYSTEM
5.9.2 KEY PLAYERS IN IMMUNOASSAY MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 22 PORTER’S FIVE FORCES
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT FROM NEW ENTRANTS
5.11 KEY CONFERENCES & EVENTS IN 2023–2024
TABLE 23 KEY CONFERENCES & EVENTS IN 2023–2024
5.12 PRICING ANALYSIS
TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 26 KEY BUYING CRITERIA, BY TOP END USER
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 IMMUNOASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 27 IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 28 KEY REAGENTS & KITS AVAILABLE
TABLE 29 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
6.2.1 ELISA REAGENTS & KITS
6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.2 RAPID TEST REAGENTS & KITS
6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment
TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.3 ELISPOT REAGENTS & KITS
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment
TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.4 CLIA REAGENTS & KITS
6.2.4.1 Better diagnosis and higher specificity to drive segment
TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.5 IFA REAGENTS & KITS
6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment
TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.6 WESTERN BLOT REAGENTS & KITS
6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.7 OTHER REAGENTS & KITS
TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 ANALYZERS
TABLE 38 KEY ANALYZERS AVAILABLE
TABLE 39 IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE
TABLE 40 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
6.3.1.1 Open-ended systems
6.3.1.1.1 Better flexibility and wider availability to drive segment
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.2 Closed-ended systems
6.3.1.2.1 Higher precision and better automation to drive segment
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.2 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE
TABLE 43 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
6.3.2.1 Rental purchase
6.3.2.1.1 Increased convenience and lack of liability to drive segment
TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.2.2 Outright purchase
6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market
TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 IMMUNOASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 ELISA
7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE
TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION)
7.3 CLIA
7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET
TABLE 49 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021–2028 (USD MILLION)
7.4 IFA
7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
TABLE 50 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION)
7.5 RAPID TESTS
7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET
TABLE 51 KEY RAPID TESTS AVAILABLE
TABLE 52 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION)
7.6 WESTERN BLOTTING
7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET
TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE
TABLE 54 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION)
7.7 ELISPOT
7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET
TABLE 55 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION)
7.8 OTHER TECHNOLOGIES
TABLE 56 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 IMMUNOASSAY MARKET, BY SPECIMEN
8.1 INTRODUCTION
TABLE 57 IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
8.2 BLOOD
8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET
TABLE 58 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
8.3 SALIVA
8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
TABLE 59 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
8.4 URINE
8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET
TABLE 60 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SPECIMENS
TABLE 61 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2028 (USD MILLION)
9 IMMUNOASSAY MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 62 IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 63 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
TABLE 64 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 CARDIOLOGY
9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS
TABLE 66 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.5 AUTOIMMUNE DISORDERS
9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
TABLE 67 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET
TABLE 68 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
9.7 ONCOLOGY
9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET
TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
TABLE 70 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.8 BONE & MINERAL DISORDERS
9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET
TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
TABLE 72 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.9 DRUG MONITORING AND TESTING
9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
TABLE 73 KEY PRODUCTS FOR DRUG MONITORING
TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING
TABLE 75 IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING, BY REGION, 2021–2028 (USD MILLION)
9.10 BLOOD SCREENING
9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET
TABLE 76 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING
TABLE 78 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.12 OTHER APPLICATIONS
TABLE 79 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 IMMUNOASSAY MARKET, BY END USER
10.1 INTRODUCTION
TABLE 80 IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET
TABLE 81 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
TABLE 82 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET
TABLE 83 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.5 HOME CARE SETTINGS
10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET
TABLE 84 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
10.6 BLOOD BANKS
10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET
TABLE 85 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
10.7 RESEARCH & ACADEMIC LABORATORIES
10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET
TABLE 86 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
11 IMMUNOASSAY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 87 IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 88 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market
TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 101 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 103 US: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 US: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market
TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 106 CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 109 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 110 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 111 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 112 CANADA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 118 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 121 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Germany to dominate European immunoassay market during forecast period
TABLE 122 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 128 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 ITALY
11.3.3.1 Growing geriatric population and increasing support for research to drive market
TABLE 130 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 134 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 136 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market
TABLE 138 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 139 FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 142 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 143 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 144 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market
TABLE 146 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 147 SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 150 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 151 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 152 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 UK
11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
TABLE 154 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 155 UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 158 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 159 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 160 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 RUSSIA
11.3.7.1 Lack of reimbursement and delays in approval to limit market
TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 163 RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 166 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 167 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 168 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.8 REST OF EUROPE
TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 171 REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 173 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 174 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 175 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 176 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
TABLE 178 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 183 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 185 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 JAPAN
11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market
TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 188 JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 189 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 191 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 192 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 193 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Increasing government investment and rising geriatric population to drive market
TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 196 CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 199 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 200 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 201 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 204 INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 205 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 207 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 208 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 209 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market
TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 212 AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 214 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 215 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 216 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 217 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising healthcare spending and investments in research to drive market
TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 220 SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 221 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 223 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 224 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 225 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.7 INDONESIA
11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market
TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 228 INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 230 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 231 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 232 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 233 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.8 REST OF ASIA PACIFIC
TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 239 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 240 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 241 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 LATIN AMERICA
TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 244 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 246 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 248 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 249 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022
TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 253 BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 255 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 256 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 257 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 258 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Increasing geriatric population and rising medical tourism to drive market
TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 261 MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 262 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 263 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 264 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 265 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 266 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET
12.3 REVENUE ANALYSIS
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY MARKET
FIGURE 37 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 COMPANY EVALUATION MATRIX, 2022
12.5.5 COMPANY FOOTPRINT
TABLE 286 OVERALL FOOTPRINT
TABLE 287 PRODUCT FOOTPRINT
TABLE 288 REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET
12.7 COMPETITIVE SCENARIOS AND TRENDS
12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023
12.7.2 KEY DEALS
TABLE 291 KEY DEALS, JANUARY 2020–SEPTEMBER 2023
12.7.3 OTHER KEY DEVELOPMENTS
TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ABBOTT LABORATORIES
TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
13.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.3 SIEMENS HEALTHINEERS AG
TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
13.1.4 DANAHER CORPORATION
TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.5 THERMO FISHER SCIENTIFIC INC.
TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
13.1.6 REVVITY
TABLE 298 REVVITY: COMPANY OVERVIEW
FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022)
13.1.7 BECTON, DICKINSON AND COMPANY
TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.8 DIASORIN S.P.A.
TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.9 BIO-RAD LABORATORIES, INC.
TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
13.1.10 QUIDELORTHO CORPORATION
TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
13.1.11 BIOMЙRIEUX
TABLE 303 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 50 BIOMЙRIEUX: COMPANY SNAPSHOT (2022)
13.1.12 QIAGEN N.V.
TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
13.1.13 SYSMEX CORPORATION
TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
13.1.14 AGILENT TECHNOLOGIES, INC.
TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 MERCK KGAA
13.2.2 MERIDIAN BIOSCIENCE
13.2.3 BIO-TECHNE
13.2.4 CELLABS
13.2.5 ABNOVA CORPORATION
13.2.6 J. MITRA & CO. PVT. LTD.
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE)
13.2.8 CELL SCIENCES
13.2.9 ENZO BIOCHEM
13.2.10 CREATIVE DIAGNOSTICS
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
13.2.12 ELABSCIENCE
13.2.13 WAK-CHEMIE MEDICAL
13.2.14 SERACARE LIFESCIENCES INC.
13.2.15 EPITOPE DIAGNOSTICS
13.2.16 KAMIYA BIOMEDICAL COMPANY
13.2.17 GYROS PROTEIN TECHNOLOGIES
13.2.18 TRIVITRON HEALTHCARE
13.2.19 INBIOS INTERNATIONAL, INC.
13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
